Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-04-23
2009-08-25
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07579331
ABSTRACT:
Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.
REFERENCES:
patent: 4769377 (1988-09-01), Sayder et al.
patent: 5290782 (1994-03-01), Suzuki et al.
patent: 5395836 (1995-03-01), Shimada et al.
patent: 5446046 (1995-08-01), Belardinelli et al.
patent: 5532368 (1996-07-01), Kufner-Muhl et al.
patent: 5599817 (1997-02-01), Adamus et al.
patent: 5631260 (1997-05-01), Belardinelli et al.
patent: 5641784 (1997-06-01), Küfner-Mühl et al.
patent: 5668139 (1997-09-01), Belardinelli et al.
patent: 5688802 (1997-11-01), Kufner-Muhl et al.
patent: 5696124 (1997-12-01), Kufner-Muhl et al.
patent: 5736528 (1998-04-01), Belardinelli et al.
patent: 6187780 (2001-02-01), Blech et al.
patent: 6210687 (2001-04-01), Hosokawa et al.
patent: 6254889 (2001-07-01), Kigoshi et al.
patent: 6605600 (2003-08-01), Ensinger et al.
patent: 6649600 (2003-11-01), Kiesman et al.
patent: 6818647 (2004-11-01), Wolff et al.
patent: 7022686 (2006-04-01), Lin et al.
patent: 2002/0115687 (2002-08-01), Beckman et al.
patent: 2002/0136775 (2002-09-01), Thosar et al.
patent: 2004/0229901 (2004-11-01), Otsuki et al.
patent: 2004/0259889 (2004-12-01), Smits et al.
patent: 2005/0038017 (2005-02-01), Wolff et al.
patent: 2005/0070524 (2005-03-01), Stephenson et al.
patent: 2005/0239759 (2005-10-01), Otsuki et al.
patent: 2005/0245546 (2005-11-01), Cristalli
patent: 2006/0030572 (2006-02-01), Widder et al.
patent: 2006/0035911 (2006-02-01), Widder et al.
patent: 2006/0293312 (2006-12-01), Dittrich et al.
patent: 2007/0238672 (2007-10-01), Dittrich et al.
patent: 2007/0293463 (2007-12-01), Dittrich et al.
patent: 2007/0293518 (2007-12-01), Dittrich et al.
patent: 2008/0070934 (2008-03-01), Mugerditchian et al.
patent: 0 565 377 (1993-10-01), None
patent: 0 619 316 (1994-10-01), None
patent: 0 958 821 (1999-11-01), None
patent: 0 970 696 (2000-01-01), None
patent: 1979/79296 (1979-06-01), None
patent: 1984/42383 (1984-03-01), None
patent: WO 91/10428 (1991-07-01), None
patent: WO 93/00081 (1993-01-01), None
patent: WO 94/03456 (1994-02-01), None
patent: WO 99/54331 (1999-10-01), None
patent: WO 99/55339 (1999-11-01), None
patent: WO 01/15673 (2001-03-01), None
patent: WO 01/34604 (2001-05-01), None
patent: WO 02/44182 (2002-06-01), None
patent: WO 02/49645 (2002-06-01), None
patent: WO 2004/075856 (2004-09-01), None
patent: WO 2004/096228 (2004-11-01), None
patent: WO 2007/117549 (2007-10-01), None
patent: WO 2007/149366 (2007-12-01), None
U.S. Appl. No. 10/785,446, filed Feb. 23, 2004, Otsuki et al.
Aki et al.; “Effects of KW-3902, a Selective and Potent Adenosine A1 Receptor Antagonist, on Renal Hemodynamics and Urine Formation in Anesthetized Dogs,”Pharmacology. (1997); 55:193-201.
Barrett Richard J., “Realizing the Potential of Adenosine-Receptor-Based Therapeutics,”Proc. West. Pharmacol. Soc. (1996);39:61-66.
Belardinelli et al.; “1,3 Dipropyl-8-[2-(5,6-Epoxy)Norbornyl]Xanthine, a Potent Specific and Selective A1Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT1MF-2 Cells,”Journal of Pharmacology and Experimental Theraputics. (1995); 275(3):1167-1176.
Bertolet et al., “Differential antagonism of cardiac actions of adenosine by theophylline,”Cardiovascular Research. (1996);32:839-845.
Broadley, Kenneth J.; “Drugs modulating adenosine receptors as potential therapeutic agents for cardiovascular diseases,”Exp. Opin. Ther. Patents. (2000); 10(11):1669-1692.
Conlon et al.,. “Effect of Intravenous Furosemide on Serum Theophylline Concentration,”Am. J. Hosp. Pharm. (1981);38:1345-7.
Deckert et al., “Adenosine A1receptors in human hippocampus: inhibition of [3H]8-cyclopentyl-1,3-dipropylxanthine binding by antagonist drugs,”Neuroscience Letters. (1993);150:191-194.
Daghfous et al., “Fasting in Ramadan, the asthmatics and sustained-release theophylline,” Annals of Saudi Medicine. (1994).
Gellai et al., “CVT-124, a novel adenosine A1receptor antagonist with unique diuretic activity,”J. Pharmacol. Exp. Ther. (1998);286(3):1191-6.
Giacoia et al., “Diuretics, Hypochloremia, and Outcome in Bronchopulmonary Dysplasia Patients,”Dev. Pharmacol. Ther. (1991);4:212-220.
Gottlieb, Stephen S.; “Renal Effects of Adenosine A1-Receptor Antagonists in Congestive Heart Failure,”Drugs. (2001); 61(10):1387-1393.
Gottleib et al.; “BG9719 (CVT-124), an Adenosine A1Receptor Antagonist, Protects Against the Decline in Renal Function Observed with Diuretic Therapy,”Circulation. (2002); 105(11):1348-1353.
Gottleib et al.; “BG9719 (CVT-124), an A1-Adenosine Receptor Antagonist, Preserves Glomerular Filtration Rate and is an Active Natriuretic in Congestive Heart Failure Patients,”Circulation. (1998); 98(17):105.
Gottlieb et al., “Effects of BG9719 (CVT-124), an A1—adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure,”J. Am. Coll. Cardiol. (2000);35(1)56-9.
Greenberg et al.; “An Oral Adenosine Antagonist, Preserves Renal Function, Improves Sodium Excretion and is Well Tolerated in Heart Failure Patients,”AHA Meeting Orlando, Florida. Poster/Abstract.
Ireland et al.; “FK-352 Adenosine A1Antagonist Diuretic Antihypertensive,”Drugs of the Future. (1997); 22(4):350-352.
Jackson, Edwin K.; “A1 receptor antagonists as diuretic
atriuretic agents,”Drugs of the Future.
Jackson et al.; “A1Receptor Blockade Induces Natriuresis with a Favorable Renal Hemodynamic Profile in SHHF/Mcc-fa(cp) Rats Chronically Treated with Salt and Furosemide,”Journal of Pharmacology and Experimental Theraputics.(2001); 299(3):978-987.
Kobayashi et al.; “Diuretic Effects of KW-3902 (8-(Noradamantan-3-yl)-1,3-dipropylxanthine), a Novel Adenosine A1Receptor Antagonist, in Conscious Dogs,”Biol. Pharm. Bull. (1993); 16(12):1231-1235.
Lasser, Richad P. “The Treatment of Heart Failure in the ‘Intractable’ (Refractory) Phase,”Advances in Cardiopulmonary Diseasesvol. III. Banyai et al. Ed. (1966);3:296-304.
Lucas et al.; “Novel Effects of Selective Adenosine Subtype 1(A1) Receptor Inhibition on Renal and Pulmonary Function in Heart Failure,”Surgical Forum. (2001); 52:95-97.
Lucas et al. “Effects of Adenosine Receptor Subtype A1on Ventricular and Renal Function,”Journal of Cardiovascular Pharmacology. (2003); 38(4):618-624.
Lucas et al.; “Cardiorenal Effects of Adenosine Subtype 1(A1) Receptor Inhibition in an Experimental Model of Heart Failure,”J. American College of Surgeons: (2002); 194(5):603-609.
Macolić et al., “Pharmacokinetics and interactions of digoxin theophylline and furosemide in diseases with edema,”International Journal of Clinical Pharmacology, Therapy and Toxicology(1993);31(1):6-11.
Mazkereth et al., “Effects of theophylline on renal function in premature infants,”American Journal of Perinatology(1997);14(1):45-49.
Merzon et al., “Effect of euphylline and lasix on the urea-excretion function of the kidneys in cardiac insufficiency,”Sov. Med. (1971);34(5):119-24.
Oberbauer et al.; “Natriuretic effect of adenosineA1-receptor blockade in rats,”Nephrology, Dialysis, Transplantation. (1998);13(4):900-3.
Patterson et al.; “Selective A1Adenosine Receptor Antagonism Improves Renal Function in Heart Failure,”Circulation. (2000); 102(18):158.
Pfister et al.; “Synthesis and Biological Evaluation of the Enantiomer
Blantz Roland
Dittrich Howard C.
Otsuki Lauren
Thomson Scott
Widder Kenneth J.
Daniel Mark R.
Henley, III Raymond J
Novacardia, Inc.
Parr Richard S.
LandOfFree
Method of improved diuresis in individuals with impaired... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of improved diuresis in individuals with impaired..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of improved diuresis in individuals with impaired... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4071850